A test for anti-TNF non-responders? Few alternative RA therapies available

Tumor necrosis factor (TNF) inhibitors, such as Amgen's Enbrel (etanercept) and AbbVie's Humira (adalimumab), are the biologics of choice to treat rheumatoid arthritis (RA) patients. But many people with the debilitating autoimmune disease don't respond to anti-TNF therapies, so what if you could identify patients early on who won't respond to those biologics?

Tumor necrosis factor (TNF) inhibitors, such as Amgen's Enbrel (etanercept) and AbbVie's Humira (adalimumab), are the biologics of choice to treat rheumatoid arthritis (RA) patients. But many people with the debilitating autoimmune disease don't respond to anti-TNF therapies, so what if you could identify patients early on who won't respond to those biologics?

Cambridge, Massachusetts-based Selventa is developing a test to identify people with RA who won't respond to anti-TNF drugs, the results...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category